1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-14.70%
Cash & equivalents declining -14.70% while Drug Manufacturers - Specialty & Generic shows 0.00% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-14.70%
Below half the Drug Manufacturers - Specialty & Generic median of 0.00% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
53.57%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
37.86%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 1.12%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
506.16%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
4.65%
Current assets growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 1.26%. Joel Greenblatt sees a potential liquidity edge if well allocated.
7.18%
PP&E growth below half of Drug Manufacturers - Specialty & Generic median of -0.94%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
6.05%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
5.76%
Intangibles growth < half the Drug Manufacturers - Specialty & Generic median of -1.18%. Joel Greenblatt sees fewer intangible expansions vs. peers. Possibly less impairment risk.
5.94%
Below half of Drug Manufacturers - Specialty & Generic median of -0.59%. Joel Greenblatt sees relatively minimal intangible expansions vs. peers.
-12.45%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
251658340.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
No Data
No Data available this quarter, please select a different quarter.
6.29%
Below half the Drug Manufacturers - Specialty & Generic median of -0.21%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
5.69%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.59%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
131.05%
Payables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
119.36%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
257.07%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-100.00%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
3.31%
Below half Drug Manufacturers - Specialty & Generic median of -0.31%. Joel Greenblatt sees more conservative short-term leverage than peers.
4.99%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
-3.34%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential shortage of multi-year commitments.
-11.47%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
-47.88%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
2.70%
Below half Drug Manufacturers - Specialty & Generic median of -1.35%. Joel Greenblatt sees more conservative long-term liability expansion vs. peers.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects hidden or rapidly growing miscellaneous liabilities.
2.86%
Below half Drug Manufacturers - Specialty & Generic median of -0.70%. Joel Greenblatt sees a much lower liability expansion vs. peers.
6.80%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-41.91%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects poor profitability or large dividend drains.
200.85%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
-182.33%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
5.81%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 2.06%. Joel Greenblatt sees stronger equity growth vs. peers.
5.69%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.70%. Joel Greenblatt sees more aggressive expansions than peers.
-12.45%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
8.09%
Below half Drug Manufacturers - Specialty & Generic median of -0.16%. Joel Greenblatt sees a stronger deleveraging trend than peers.
132.42%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
